June 24, 2026, 1 pm ET/10 am PT
Recombinant antibodies have become foundational to modern biopharma, offering the consistency, scalability, and engineering precision needed to support today’s most advanced therapeutic modalities, including antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs). Their defined sequences and customizable formats enable reproducible performance across discovery and development, helping teams generate higher-quality data and make more confident decisions, faster.
In contrast to traditional antibodies, recombinant platforms allow for precise, site-specific modification and simplified integration into complex workflows. This level of control is critical for conjugation strategies, assay development, and analytical reproducibility—ultimately reducing variability and de-risking therapeutic programs.
This seminar will highlight how recombinant antibodies enable robust, high-confidence workflows for conjugate development and characterization. Through focused technical insights and case examples, attendees will see how site-specific labeling and engineered antibody formats improve data quality, streamline workflows, and support clearer interpretation of antibody behavior in biologically relevant systems.
Attendees will learn how to:
- Improve reproducibility and scalability with recombinant antibody platforms
- Enable precise, site-specific conjugation of ADCs and antibody-oligo therapeutics
- Generate the high-quality, quantitative data across key analytical workflows
- Reduce development risk with well-defined, engineerable antibody reagents
Offered Free by: Thermo Fisher Scientific | Biocompare
See All Resources from: Thermo Fisher Scientific | Biocompare
